Absci

Revenue is milestone- and services-based and highly volatile: 2025 revenue was 2.8 million, down from 4.5 million in 2024, with three partners comprising 95 percent of 2025 partner revenue.

Management itself warns revenue will fluctuate with the timing of partnerships and milestones, and as of March 24, 2026 no partner had licensed Absci IP for clinical or commercial use. The business model is thus dependent on unpredictable clinical and deal events rather than recurring, diversified revenue.